Showing results (1-10 of 25) with videos related to
Sort By:
Pageof 3
British Journal of Clinical Pharmacology|May 17, 2018
Dipeptidyl peptidase-4 inhibitor use is associated with decreased risk of fracture in patients with type 2 diabetes: a population-based cohort studyWen-Hsuan Hou, Kai-Cheng Chang, Chung-Yi Li, et al.Journal of Diabetes|April 11, 2016
Recent trends in the use of antidiabetic medications from 2008 to 2013: A nation-wide population-based study from TaiwanHuang-Tz Ou, Kai-Cheng Chang, Ya-Ming Liu, et al.Pain|April 30, 2016
Dipeptidyl peptidase-4 inhibitor use is not associated with elevated risk of severe joint pain in patients with type 2 diabetes: a population-based cohort studyWen-Hsuan Hou, Kai-Cheng Chang, Chung-Yi Li, et al.British Journal of Clinical Pharmacology|January 22, 2017
Comparative cardiovascular risks of dipeptidyl peptidase 4 inhibitors with other second- and third-line antidiabetic drugs in patients with type 2 diabetesHuang-Tz Ou, Kai-Cheng Chang, Chung-Yi Li, et al.Cardiovascular Diabetology|March 3, 2016
Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal studyHuang-Tz Ou, Kai-Cheng Chang, Chung-Yi Li, et al.International Journal of Cardiology|January 8, 2017
Intensive statin regimens for reducing risk of cardiovascular diseases among human immunodeficiency virus-infected population: A nation-wide longitudinal cohort study 2000-2011Huang-Tz Ou, Kai-Cheng Chang, Chung-Yi Li, et al.Cancers|March 10, 2022
Comparative Effectiveness and Safety of Standard-Dose and Low-Dose Pembrolizumab in Patients with Non-Small-Cell Lung Cancer: A Multi-Institutional Cohort Study in TaiwanKai-Cheng Chang, Shih-Chieh Shao, Hui-Yu Chen, et al.Journal of Orthopaedic Surgery (Hong Kong)|June 7, 2026
Automating methodological quality assessment in orthopedic systematic reviews using large language modelsYu-Jui Huang, Kai-Cheng Chang, Ying-Chen Kuo, et al.Cardiovascular Diabetology|October 18, 2024
Non-alcoholic fatty liver disease risk with GLP-1 receptor agonists and SGLT-2 inhibitors in type 2 diabetes: a nationwide nested case-control studyKai-Cheng Chang, Fan-Chi Kuo, Chen-Yi Yang, et al.Emerging Infectious Diseases|October 14, 2021
Guillain-Barré Syndrome Associated with COVID-19 VaccinationShih-Chieh Shao, Chien-Ho Wang, Kai-Cheng Chang, et al.Pageof 3